Alexion Pharmaceuticals (ALXN)
Add to Watchlists Create an AlertAlexion Pharmaceuticals R&D Expense Quarterly:
74.54M for March 31, 2013Alexion Pharmaceuticals Historical R&D Expense Quarterly Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 74.54M |
| Dec. 31, 2012 | 63.41M |
| Sept. 30, 2012 | 54.28M |
| June 30, 2012 | 59.64M |
| March 31, 2012 | 45.41M |
| Dec. 31, 2011 | 34.40M |
| Sept. 30, 2011 | 36.57M |
| June 30, 2011 | 35.65M |
| March 31, 2011 | 30.81M |
| Dec. 31, 2010 | 27.18M |
| Sept. 30, 2010 | 25.15M |
| June 30, 2010 | 23.69M |
| March 31, 2010 | 22.37M |
| Dec. 31, 2009 | 23.22M |
| Sept. 30, 2009 | 21.32M |
| June 30, 2009 | 18.29M |
| March 31, 2009 | 19.09M |
| Dec. 31, 2008 | 15.28M |
| Sept. 30, 2008 | 14.87M |
| June 30, 2008 | 16.82M |
| March 31, 2008 | Go Pro |
| Dec. 31, 2007 | Go Pro |
| Sept. 30, 2007 | Go Pro |
| June 30, 2007 | Go Pro |
| March 31, 2007 | Go Pro |
| Dec. 31, 2006 | Go Pro |
| Sept. 30, 2006 | Go Pro |
| June 30, 2006 | Go Pro |
| March 31, 2006 | Go Pro |
| Oct. 31, 2005 | Go Pro |
| July 31, 2005 | Go Pro |
| April 30, 2005 | Go Pro |
| Jan. 31, 2005 | Go Pro |
| Oct. 31, 2004 | Go Pro |
| July 31, 2004 | Go Pro |
| April 30, 2004 | Go Pro |
| Jan. 31, 2004 | Go Pro |
| Oct. 31, 2003 | Go Pro |
| July 31, 2003 | Go Pro |
| April 30, 2003 | Go Pro |
| Jan. 31, 2003 | Go Pro |
| Oct. 31, 2002 | Go Pro |
| July 31, 2002 | Go Pro |
| April 30, 2002 | Go Pro |
| Jan. 31, 2002 | Go Pro |
| Oct. 31, 2001 | Go Pro |
| July 31, 2001 | Go Pro |
| April 30, 2001 | Go Pro |
| Jan. 31, 2001 | Go Pro |
| Oct. 31, 2000 | Go Pro |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
ALXN R&D Expense Quarterly Benchmarks
| Companies | |
|---|---|
| Vertex Pharmaceuticals | 218.10M |
| Regeneron Pharmaceuticals | 180.30M |
| Athersys | 4.935M |
ALXN R&D Expense Quarterly Rankings
| Overall |
98th percentile 153 of 8009 |
| Sector |
94th percentile 40 of 687 in Healthcare |
| Industry |
95th percentile 12 of 248 in Biotechnology |
ALXN R&D Expense Quarterly Range, Past 5 Years
| Minimum | 14.87M | Sep 2008 |
| Maximum | 74.54M | Mar 2013 |
| Average | 33.10M |
ALXN News
Business Wire May 23